Semaglutide
Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist peptide that suppresses appetite and supports weight loss, with up to 14.9% reduction in STEP-1.
Total Price
฿2500
For research & laboratory use only. Not for human consumption.
Half-Life
7 days
Administration Route
Subcutaneous injection
14.9% Weight Reduction
Clinically validated in 68-week STEP-1 Phase 3 trial
Cardiovascular Benefit
Reduced MACE risk in the SUSTAIN-6 outcomes trial
Blood Sugar Control
GLP-1R agonism drives glucose-dependent insulin release
Effect Timeline
Hunger signals blunted; food cravings significantly reduced
2–4% body weight reduction; nausea subsides
Consistent fat loss; HbA1c begins declining
6–10% weight loss; cardiovascular markers improve
Start — Week 1–2
Hunger signals blunted; food cravings significantly reduced
Week 4
2–4% body weight reduction; nausea subsides
Week 8
Consistent fat loss; HbA1c begins declining
Week 16
6–10% weight loss; cardiovascular markers improve
Mechanism of Action
Scientific Research
New England Journal of Medicine (2021)
New England Journal of Medicine (2016)
Why Researchers Choose Semaglutide
Semaglutide (the long-acting GLP-1 receptor agonist marketed as Ozempic and Wegovy) is the reference incretin compound for metabolic research, valued because its roughly seven-day half-life enables stable once-weekly dosing. It is studied wherever appetite regulation, glycaemic control and GLP-1 pharmacology intersect:
- Appetite regulation and hypothalamic satiety signalling research
- Glycaemic control and pancreatic beta cell function studies
- Cardiovascular risk marker reduction in metabolic disease models
- Comparison protocols against newer dual and triple receptor agonists
- Non-alcoholic fatty liver disease (NAFLD) progression studies
- Neuroinflammation and neuroprotection investigations via central GLP-1 receptors
How Semaglutide Works
Semaglutide is a modified GLP-1 analog carrying a C18 fatty-acid chain that binds reversibly to albumin, which is what extends its half-life to roughly a week and protects it from rapid DPP-4 degradation. It engages GLP-1 receptors across three tissues at once: in the pancreas it drives glucose-dependent insulin secretion and suppresses glucagon, in the gastrointestinal tract it slows gastric emptying, and in the hypothalamus it activates central satiety circuits that reduce appetite. The combination of lower food intake and improved glucose handling is the dual mechanism behind both its metabolic and weight-management effects.
Semaglutide vs. Tirzepatide
Semaglutide is a single-receptor (GLP-1) agonist, while tirzepatide adds GIP receptor activity as a dual agonist and retatrutide extends this further to a GLP-1, GIP and glucagon triple agonist. In trials the multi-receptor compounds produced larger weight reductions, which makes head-to-head pharmacology a common research focus. See the full semaglutide vs. tirzepatide comparison for a side-by-side breakdown.
Dosage Information
Titration: escalate once weekly, roughly every 4 weeks: 0.25mg (weeks 1-4) to 0.5mg to 1mg to 1.7mg to 2.4mg from week 17 onward. The 2.4mg weekly dose produced the largest weight reduction in the STEP trials.
Storage and Reconstitution
Reconstitution: use bacteriostatic water (1-2ml per vial); swirl gently until dissolved, do not shake. Protect from light. After reconstitution: keep refrigerated at 2-8°C and use within 28 days.
Dosing at a Glance
Route
Subcutaneous injection
Frequency
Once weekly
Typical research dose
0.25–2.4 mg
Opens the calculator with this peptide preselected. Research reference only.
Product FAQs
Customer Reviews
I tried it for the first time at a minimal dosage of 0.25 per week. By the second week, the effect was already great — it became much easier to stick to my routine, and I stopped snacking out of habit. The constant hunger I always used to have is no longer there. The only downside is that there's no option to buy 5 vials of 1mg each. Based on my calculations, a single 5mg vial will last me more than two months, so I'll have to throw away the leftovers since they'll spoil before I can finish them.
This is the second time I've used Semaglutide, and once again the quality and results are noticeable within 24 hours of starting it. I followed the recommended dosages and had no side effects whatsoever, apart from the most desirable one: my hunger and midnight cravings stopped almost immediately. Milo Lab has other options beyond Semaglutide, but if you're looking to test the water on these weight loss products on a smaller budget, Semaglutide is a great option. I exercise daily by running and have had consistent problems with sugar cravings, and those cravings stopped within 24 hours of starting it. It's also very convenient, with the injection only required once a week. Overall an excellent product, with outstanding quality control from Milo Lab.
Used in Research Stacks
Semaglutide Weight Loss Stack
Related Products
Tirzepatide
Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist peptide that lowers blood sugar and drives weight loss, with up to 22.5% loss in trials.
Retatrutide
Retatrutide (LY3437943) is Eli Lilly's investigational triple-receptor peptide targeting GLP-1, GIP and glucagon, with up to 24.2% weight loss in Phase 2.